NASDAQ:PRAH - PRA Health Sciences Stock Price, News, & Analysis

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) released its earnings results on Wednesday, October, 31st. The medical research company reported $1.13 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.07 by $0.06. The medical research company earned $717.60 million during the quarter, compared to the consensus estimate of $729.63 million. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. The business's revenue for the quarter was up 23.3% on a year-over-year basis. During the same period last year, the business posted $0.88 earnings per share. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for PRA Health Sciences.

8 Wall Street analysts have issued 12-month target prices for PRA Health Sciences' stock. Their predictions range from $100.00 to $120.00. On average, they anticipate PRA Health Sciences' stock price to reach $113.50 in the next year. This suggests that the stock has a possible downside of 0.6%. View Analyst Price Targets for PRA Health Sciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PRA Health Sciences.

Press coverage about PRAH stock has trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. PRA Health Sciences earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Some companies that are related to PRA Health Sciences include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL).

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include Alibaba Group (BABA), NVIDIA (NVDA), General Electric (GE), Twitter (TWTR), Mattel (MAT), Ultra Clean (UCTT), Paypal (PYPL), Adobe (ADBE), salesforce.com (CRM) and Chevron (CVX).

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.48%), Bank of New York Mellon Corp (3.37%), Eagle Asset Management Inc. (1.64%), Pendal Group Ltd (1.36%), Frontier Capital Management Co. LLC (1.34%) and Jennison Associates LLC (1.33%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Acadian Asset Management LLC, Swedbank, Bank of America Corp DE, Los Angeles Capital Management & Equity Research Inc., Vaughan Nelson Investment Management L.P., Gotham Asset Management LLC and Mitchell Capital Management Co.. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was bought by a variety of institutional investors in the last quarter, including Pendal Group Ltd, Standard Life Aberdeen plc, Millennium Management LLC, Prudential Financial Inc., First Trust Advisors LP, Frontier Capital Management Co. LLC, Assenagon Asset Management S.A. and Mackay Shields LLC. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $114.13.

PRA Health Sciences has a market capitalization of $7.42 billion and generates $2.26 billion in revenue each year. The medical research company earns $86.92 million in net income (profit) each year or $3.20 on an earnings per share basis. PRA Health Sciences employs 15,800 workers across the globe.

The official website for PRA Health Sciences is http://www.prahs.com.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]